PPARG and Alzheimer disease: Recently, an exploratory phase IIa clinical trial investigated the effects of dual PPARγ/PPARΔ agonist, T3D-959, in subjects with mild to moderate AD; T3D-959 was well-tolerated, and patients exhibited cognitive improvements [154].